The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used
- 6 February 2013
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 48 (1) , 32-54
Abstract
Contemporary natural history data in Duchenne muscular dystrophy (DMD) is needed to assess care recommendations and aid in planning future trials.Methods: The Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DMD‐NHS) enrolled 340 individuals, aged 2–28 years, with DMD in a longitudinal, observational study at 20 centers. Assessments obtained every 3 months for 1 year, at 18 months, and annually thereafter included: clinical history; anthropometrics; goniometry; manual muscle testing; quantitative muscle strength; timed function tests; pulmonary function; and patient‐reported outcomes/health‐related quality‐of‐life instruments.Results: Glucocorticoid (GC) use at baseline was 62% present, 14% past, and 24% GC‐naive. In those ≥6 years of age, 16% lost ambulation over the first 12 months (mean age 10.8 years).Conclusions: Detailed information on the study methodology of the CINRG DMD‐NHS lays the groundwork for future analyses of prospective longitudinal natural history data. These data will assist investigators in designing clinical trials of novel therapeutics. Muscle Nerve, 2013Keywords
This publication has 101 references indexed in Scilit:
- Neuro-QOLNeurology, 2012
- Linking the Activity Measure for Post Acute Care and the Quality of Life Outcomes in Neurological DisordersArchives of Physical Medicine and Rehabilitation, 2011
- The Neurology Quality-of-Life Measurement InitiativeArchives of Physical Medicine and Rehabilitation, 2011
- Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophyNeurology, 2011
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyThe Lancet, 2011
- The PedsQL™ in pediatric patients with Spinal Muscular Atrophy: Feasibility, reliability, and validity of the Pediatric Quality of Life Inventory™ Generic Core Scales and Neuromuscular ModuleNeuromuscular Disorders, 2009
- Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohortHuman Mutation, 2009
- The Patient-Reported Outcomes Measurement Information System (PROMIS)Medical Care, 2007
- Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001Value in Health, 2003
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992